News MMJ Hires Lead Investigator for Phase 2 Trials of Medicinal Cannabis to Treat Progressive MS MMJ Hires Lead Investigator for Phase 2 Trials of Medicinal Cannabis to Treat Progressive MS by Patricia Silva, PhD | November 14, 2017 Share this article: Share article via email Copy article link MMJ BioScience, an affiliate of medical cannabis research company MMJ International Holdings, has hired a principal investigator to lead clinical trials exploring potential therapeutic applications of cannabinoids inĀ progressive multiple sclerosis (MS). Dr. Bianca Weinstock-Guttman, a neurology professor at the State University of New York at Buffalo,Ā is executive director of the New York State Multiple Sclerosis Consortium. SheĀ will lead Phase 2 clinical trials, which have already been cleared by the U.S. Food and Drug Administration (FDA), with the guidance of Parexel, a clinical research organization. “There is a considerable body of evidence to suggest that cannabis may have a number of positive medicinal uses, including the relief of pain and spasm in multiple sclerosis,” company spokesman Michael Sharpe saidĀ in a press release. “We are now well on the way to being able to demonstrate this in a controlled clinical research environment.” He added: “Entering Phase 2 trials is a highly significant point in the development of our cannabis-based medicines. These trials will allow us to demonstrate efficacy in a limited number of subjects and to establish the necessary dosage regimen and delivery mechanisms to provide the most effective relief to sufferers from the acute pain and spasticity associated with MS. This is MMJās first study of cannabis-based medicines involving patients with MS and related forms of severe pain and spasticity. Patients will receive proprietary formulations of cannabis-based medicine via an oral gel cap. The trial will be conducted at several locations in New York and should begin by early 2018. It will likely involve several hundred patients over the next 18 to 24 months. Its goal is to prepareĀ data for FDA approval of a cannabis-based medicinal product. MMJ, based in Reston, Virginia, hopes to bring to market prescription medicines by 2020. These would let MS patients and others access the medical benefits of cannabis without the unwanted psychoactive side effects, or the health dangers linked to smoking. “Our aim is to test some of the claims which have been made for the medicinal qualities of cannabis in a structured clinical research program,” said Sharpe. “This is an exciting moment, and we expect that our findings will lead to significant improvements in the pain relief available for sufferers of MS.” Interest in medicinal cannabis has grown exponentially, as scientists unearth more and more benefits of the drug. Earlier this year, Ā Irish physicians voiced support for cannabis as a treatment for MS.Ā In addition,Ā medical cannabis was reported to be able to reduce MS-related neuropathic pain, and certain cannabinoids were found to reduce spasticity symptoms in MS patients. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags cannabinoids, cannabis, clinical trials, pain, progressive MS, spasticity
April 25, 2024 News by Margarida Maia, PhD Having MS may marginally increase likelihood of cervical cancer: Study
April 25, 2024 News by Marisa Wexler, MS MS patients prefer Tysabri injection to intravenous infusion: Study
April 24, 2024 News by Andrea Lobo, PhD Foralumab found to ease fatigue in SPMS patients in access program